Schedule 13G

IMCR Schedule 13G filing by T. Rowe Price Investment Management

T. Rowe Price Investment Management reported beneficial ownership of 5.2M shares, representing 10.3% of Immunocore Holdings plc in this filing.

FiledSep 10, 2024

Ownership dateAug 31, 2024

Reported shares5.2M

Reported ownership10.3%

Ownership details

Voting and dispositive power reported in the filing

These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.

Sole voting power 5.1M

Shared voting power 0

Sole dispositive power 5.2M

Shared dispositive power 0

Price context

Price dates alongside the ownership filing

Price data provides market context around the disclosure. It does not identify the filer’s actual transaction price.

Close near filing date—

Latest tracked price$33.29as of Aug 5, 2026

Source

Original filing and accession

Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.

Reporting filer: T. Rowe Price Investment Management
CIK: CIK0001897612
Accession: 0001897612-24-001390
Form: Schedule 13G

Open SEC filing View IMCR ownership history

Read the filing in context

Understand what a Schedule 13 filing does—and does not—tell you.

How to read a Schedule 13G → Does a 13G mean the shares were just bought? → Filing date vs. ownership date →